Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dulaglutide

dulaglutide

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dulaglutide

32 trials tracked of dulaglutide: 21 in phase 3 or 4 and 14 with published results. The most-cited published study has 783 citations.

32Trials tracked
21Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 6 Phase 3 15 Phase 2 4 Phase 1 7
  1. Phase 3 Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes. Completed · 783 cited
  2. Phase 3 A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Completed · 648 cited
  3. Phase 3 A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus Completed · 267 cited
  4. Phase 3 A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes Completed · 219 cited
  5. Phase 3 Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes Completed · 213 cited
  6. Phase 3 A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Completed · 193 cited
Show 26 more trials
  1. Phase 3 A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes Completed · 149 cited
  2. Phase 3 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period Completed · 83 cited
  3. Phase 3 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Completed · 20 cited
  4. Phase 4 A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Completed · 18 cited
  5. Phase 3 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) Completed · 15 cited
  6. Phase 4 A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes Completed · 11 cited
  7. Phase 4 A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Completed · 10 cited
  8. Phase 4 Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc Completed · 5 cited
  9. Phase 4 GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response Completed
  10. Phase 4 A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India Completed
  11. Phase 3 A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes Completed
  12. Phase 3 A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes Completed
  13. Phase 3 A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus Completed
  14. Phase 3 A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus Completed
  15. Phase 3 Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8) Completed
  16. Phase 2 A Study of LY3437943 in Participants With Type 2 Diabetes Completed
  17. Phase 2 A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy Completed
  18. Phase 2 A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Completed
  19. Phase 2 A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus Completed
  20. Phase 1 A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants Completed
  21. Phase 1 A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) Completed
  22. Phase 1 A Study of LY3493269 in Participants With Type 2 Diabetes Completed
  23. Phase 1 A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants Completed
  24. Phase 1 A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants Completed
  25. Phase 1 A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe Completed
  26. Phase 1 A Study of Dulaglutide in Chinese Participants Completed

Showing the 32 most-cited and recently-updated of 32 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ecnoglutide improves glycemic control and reduces body weight in adults with type 2 diabetes
Diabetes & Endocrinology Meta-analysis
Ecnoglutide improves glycemic control and reduces body weight in adults with type 2 diabetes Ecnoglutide Shows Promise for Type 2 Diabetes Management
This meta-analysis evaluated the efficacy of ecnoglutide in adults with type 2 diabetes compared to placebo and dulaglutide. The findings in…
Ecnoglutide may help manage blood sugar and reduce body weight in adults with type 2 diabetes, though more large-scale studies are needed.
Frontiers Sep 11, 2026
Comparative Efficacy of GLP-1 Receptor Agonists for Adolescent Obesity and Type 2 Diabetes
Nutrition & Obesity Medicine Sys. Review
Comparative Efficacy of GLP-1 Receptor Agonists for Adolescent Obesity and Type 2 Diabetes Trial shows different GLP-1 medications impact weight and blood sugar
A network meta-analysis evaluates GLP-1 receptor agonists in adolescents, identifying varying degrees of efficacy across weight, glucose, an…
New analysis of GLP-1 medications shows varying results for weight loss and blood sugar control in adolescents with obesity and type 2 diabe…
Sep 7, 2026
GLP-1 RA exposure in early pregnancy not significantly tied to hypertensive disorders
Diabetes & Endocrinology Meta-analysis
GLP-1 RA exposure in early pregnancy not significantly tied to hypertensive disorders GLP-1 Medications Show No Link to Pregnancy Hypertension Risk
This meta-analysis of observational cohort studies assessed the risk of hypertensive disorders of pregnancy (HDP) after periconceptional or …
A large review of over 10,000 pregnancies suggests that GLP-1 medications may not increase the risk of high blood pressure during pregnancy.
Aug 1, 2026
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
Nutrition & Obesity Medicine Meta-analysis
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials Women Lose More Weight on GLP-1 Drugs Than Men Do
This systematic review and meta-analysis examined weight changes among adults with obesity, diabetes, or cardiovascular disease treated with…
• Women lose 11% weight versus 7% for men on these drugs • Helps adults using Wegovy Ozempic and similar weight loss medications • Works sam…
May 4, 2026
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
May 1, 2026
Narrative review compares tirzepatide and semaglutide for obesity and type 2 diabetes outcomes
Rheumatology Sys. Review
Narrative review compares tirzepatide and semaglutide for obesity and type 2 diabetes outcomes New Obesity Drug Shows Stronger Weight Loss Than Popular Option
This narrative review evaluates tirzepatide versus semaglutide in individuals with obesity or type 2 diabetes mellitus.
This review shows that tirzepatide outperforms semaglutide for weight and blood sugar, but semaglutide currently has stronger proof for prot…
Frontiers Apr 22, 2026
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Cardiology RCT
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
medRxiv Apr 19, 2026
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
Neurology Sys. Review
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes A Common Medication Side Effect May Have a Surprising New Solution
This narrative review evaluates the efficacy and safety of glucocorticosteroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID…
Doctors are exploring a new way to protect patients from the dangerous blood sugar spikes caused by essential steroid medications.
Frontiers Apr 12, 2026
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
Cardiology
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes Observational study links GLP-1 RA to lower risk than SGLT2i in heart failure patients
An observational study using real-world EHR data from Stony Brook University Hospital compared GLP-1 RAs to SGLT2 inhibitors in patients wit…
In heart failure patients, GLP-1 receptor agonists showed a lower risk of death or hospitalization compared to SGLT2 inhibitors over one yea…
medRxiv Apr 9, 2026
Subgroup analysis finds tirzepatide superior to dulaglutide for HbA1c and weight in type 2 diabetes
Diabetes & Endocrinology RCT
Subgroup analysis finds tirzepatide superior to dulaglutide for HbA1c and weight in type 2 diabetes For people struggling with diabetes on dulaglutide, could switching drugs help?
This subgroup analysis of a phase IV RCT examined adults with type 2 diabetes inadequately controlled on dulaglutide.
Switching from dulaglutide to tirzepatide led to greater drops in blood sugar and body weight for adults with type 2 diabetes after 40 weeks…
Apr 8, 2026
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Nutrition & Obesity Medicine Meta-analysis
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Apr 8, 2026
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF
Cardiology Meta-analysis
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.
Apr 6, 2026

All dulaglutide Articles